Monitoring

Blood Tests to Monitor on GLP-1: What Doctors Check

GLP-1 Companion · 9 min read

Starting a GLP-1 medication is not just a matter of filling a prescription and beginning injections. Responsible prescribing involves establishing a comprehensive baseline of your metabolic health before treatment begins, then monitoring key markers at regular intervals to confirm safety and document improvement. Understanding which tests are ordered, what they measure, and what results to expect keeps you an informed and engaged participant in your own care.

Baseline Labs Before Starting

A complete baseline assessment before initiating GLP-1 therapy serves two purposes: it identifies any contraindications or precautions that might affect prescribing decisions, and it establishes reference points for measuring treatment benefits. The following labs are standard components of a pre-GLP-1 workup.

HbA1c and Fasting Glucose

HbA1c (glycated hemoglobin) reflects average blood glucose over the past 2–3 months and is the primary marker for diagnosing and managing diabetes and prediabetes. Normal: below 5.7%. Prediabetes: 5.7–6.4%. Diabetes: 6.5% or above. Fasting glucose (measured after at least 8 hours without eating) provides a snapshot of current blood sugar regulation. Normal: 70–99 mg/dL. Impaired fasting glucose (prediabetes): 100–125 mg/dL. These two tests together establish your metabolic baseline and define realistic targets for improvement.

Comprehensive Metabolic Panel (CMP)

The CMP includes tests of kidney function (creatinine, BUN, eGFR), liver function (AST, ALT, alkaline phosphatase, bilirubin), electrolytes (sodium, potassium, chloride, bicarbonate), and glucose. Kidney function is particularly important because significant renal impairment may require dose adjustments for some GLP-1 medications. Liver function establishes a baseline since non-alcoholic fatty liver disease (NAFLD) is common in patients initiating GLP-1 therapy.

Lipid Panel

A fasting lipid panel measures total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and triglycerides. Obesity and metabolic syndrome are commonly associated with elevated LDL, very high triglycerides, and low HDL — a pattern that significantly elevates cardiovascular risk. Establishing these baseline values allows your prescriber to document GLP-1-driven improvements and adjust statin or other lipid-lowering therapy as needed.

Thyroid Function (TSH)

TSH (thyroid-stimulating hormone) is measured at baseline for two reasons. First, the package labeling for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) includes a contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). While animal studies at supratherapeutic doses showed increased thyroid C-cell tumors, human epidemiological data has not confirmed increased MTC risk at therapeutic doses. Second, undiagnosed hypothyroidism can independently impair weight loss, so identifying and treating it before starting GLP-1 therapy sets you up for better outcomes.

Complete Blood Count (CBC)

A CBC measures red blood cells, white blood cells, and platelets. It screens for anemia, which could exacerbate GLP-1-associated fatigue and impair exercise tolerance. It also establishes a baseline should any unexpected blood count abnormalities arise during treatment.

What GLP-1 Medications Typically Improve

The metabolic improvements documented in clinical trials for GLP-1 medications are substantial. Understanding what to expect helps you recognize progress even when individual results vary.

• HbA1c — Reductions of 1–2 percentage points are typical in people with type 2 diabetes on semaglutide or tirzepatide. Some patients with severe baseline hyperglycemia see reductions of 2.5–3 points.
• Fasting glucose — Often normalizes (below 100 mg/dL) in patients with prediabetes within 3–6 months.
• LDL cholesterol — Modest reductions of 5–15% are common, primarily driven by weight loss.
• Triglycerides — Often the most dramatically improved lipid marker, with reductions of 15–25% or more, partly because GLP-1 receptors directly affect triglyceride-rich lipoprotein processing in the gut.
• HDL cholesterol — Modest increases of 2–5 mg/dL are typical.
• Blood pressure — Systolic blood pressure reductions of 3–6 mmHg are consistently observed in clinical trials.
• Liver enzymes (ALT, AST) — Often normalize in patients with NAFLD, reflecting reduced hepatic fat.

Ongoing Monitoring Schedule

Once GLP-1 therapy is established, monitoring frequency depends on your individual health profile. The following represents standard clinical practice.

• HbA1c — Every 3 months for the first year in patients with diabetes or prediabetes; every 6 months once stable and at goal.
• Fasting glucose — Can be monitored more frequently at home with a glucose meter if your prescriber recommends it.
• Lipid panel — Annually in most patients, or 3–6 months after a significant change in medication or diet.
• CMP (kidney and liver function) — Annually for most patients; more frequently if baseline values were abnormal.
• Blood pressure — At every clinical visit; consider a home blood pressure cuff for regular self-monitoring.
• Weight and waist circumference — At every clinical visit.

Red Flag Lab Findings

While serious adverse events are uncommon on GLP-1 medications, certain lab findings require prompt attention and communication with your prescriber.

• Elevated amylase or lipase — These enzymes are produced by the pancreas. Significant elevations (more than 2–3 times the upper limit of normal) may indicate acute pancreatitis, a rare but serious adverse effect. GLP-1 medications carry an FDA warning about pancreatitis risk, though causal evidence in humans at therapeutic doses remains debated.
• Worsening kidney function (rising creatinine, falling eGFR) — GLP-1 medications generally protect renal function, but severe volume depletion from nausea, vomiting, and reduced fluid intake can transiently worsen kidney markers.
• Significant LDL increase — Uncommon but occasionally seen. May warrant re-evaluation of statin therapy.
• Worsening liver function tests — Also uncommon; if ALT or AST rise significantly above baseline, further evaluation is warranted.

Acute pancreatitis is a rare but serious concern on GLP-1 medications. Symptoms include severe, persistent upper abdominal pain radiating to the back, often with nausea and vomiting. If you experience these symptoms, seek emergency medical care immediately — do not wait for a lab result.

Tracking Lab Trends Over Time

Keeping a personal copy of your lab results over time transforms individual numbers into a meaningful health narrative. When your HbA1c drops from 6.8% to 5.9% to 5.4% over 18 months of GLP-1 therapy, that trajectory tells a compelling story of metabolic recovery. Many electronic health record patient portals allow you to download your results — save these regularly and compare trends rather than focusing on any single test result in isolation.

Key Takeaways

• Baseline labs before starting GLP-1 should include HbA1c, fasting glucose, CMP, lipid panel, CBC, and TSH.
• Thyroid testing is specifically relevant due to MTC-related labeling contraindications.
• GLP-1 medications typically improve HbA1c by 1–2%, reduce triglycerides substantially, modestly improve LDL and blood pressure.
• HbA1c should be rechecked every 3–6 months; lipids and CMP annually.
• Elevated amylase/lipase and worsening kidney function are the key red-flag lab findings to monitor.
• Tracking your own lab results over time gives you a personal health narrative that motivates continued adherence.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.